Literature DB >> 18220275

TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse.

Alisan Kahraman1, Fernando J Barreyro, Steven F Bronk, Nathan W Werneburg, Justin L Mott, Yuko Akazawa, Howard C Masuoka, Charles L Howe, Gregory J Gores.   

Abstract

UNLABELLED: The contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a death ligand expressed by cells of the innate immune system, to cholestatic liver injury has not been explored. Our aim was to ascertain if TRAIL contributes to liver injury in the bile duct-ligated (BDL) mouse. C57/BL6 wild-type (wt), TRAIL heterozygote (TRAIL(+/-)), and TRAIL knockout (TRAIL(-/-)) mice were used for these studies. Liver injury and fibrosis were examined 7 and 14 days after BDL, respectively. Hepatic TRAIL messenger RNA (mRNA) was 6-fold greater in BDL animals versus sham-operated wt animals (P < 0.01). The increased hepatic TRAIL expression was accompanied by an increase in liver accumulation of natural killer 1.1 (NK 1.1)-positive NK and natural killer T (NKT) cells, the predominant cell types expressing TRAIL. Depletion of NK 1.1-positive cells reduced hepatic TRAIL mRNA expression and serum alanine aminotransferase (ALT) values. Consistent with a role for NK/NKT cells in this model of liver injury, stress ligands necessary for their recognition of target cells were also up-regulated in hepatocytes following BDL. Compared to sham-operated wt mice, BDL mice displayed a 13-fold increase in terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and an 11-fold increase in caspase 3/7-positive hepatocytes (P < 0.01). The number of TUNEL and caspase 3/7-positive cells was reduced by >80% in BDL TRAIL knockout animals (P < 0.05). Likewise, liver histology, number of bile infarcts, serum ALT values, hepatic fibrosis, and animal survival were also improved in BDL TRAIL(-/-) animals as compared to wt animals.
CONCLUSION: These observations support a pivotal role for TRAIL in cholestatic liver injury mediated by NK 1.1-positive NK/NKT cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220275      PMCID: PMC2570266          DOI: 10.1002/hep.22136

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  53 in total

Review 1.  Primary sclerosing cholangitis: summary of a workshop.

Authors:  Nicholas F LaRusso; Benjamin L Shneider; Dennis Black; Gregory J Gores; Stephen P James; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

Review 2.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

3.  Lysosomes and Fas-mediated liver cell death.

Authors:  Robert Wattiaux; Simone Wattiaux-de Coninck; Jacqueline Thirion; Mańe-Christine Gasingirwa; Michel Jadot
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

4.  cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis.

Authors:  Maria Eugenia Guicciardi; Steven F Bronk; Nathan W Werneburg; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-01       Impact factor: 4.052

5.  Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.

Authors:  Robert F Kelley; Klara Totpal; Stephanie H Lindstrom; Mary Mathieu; Karen Billeci; Laura Deforge; Roger Pai; Sarah G Hymowitz; Avi Ashkenazi
Journal:  J Biol Chem       Date:  2004-11-01       Impact factor: 5.157

6.  TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.

Authors:  Anil Sadarangani; Sumie Kato; Natalia Espinoza; Soledad Lange; Carmen Llados; Marisol Espinosa; Manuel Villalón; Stanley Lipkowitz; Mauricio Cuello; Gareth I Owen
Journal:  Apoptosis       Date:  2007-01       Impact factor: 4.677

7.  STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity.

Authors:  Won-Il Jeong; Ogyi Park; Svetlana Radaeva; Bin Gao
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

8.  Perforin and granzymes have distinct roles in defensive immunity and immunopathology.

Authors:  Serani L H van Dommelen; Nital Sumaria; Robert D Schreiber; Anthony A Scalzo; Mark J Smyth; Mariapia A Degli-Esposti
Journal:  Immunity       Date:  2006-11       Impact factor: 31.745

Review 9.  Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy.

Authors:  Konstantinos N Lazaridis; Jayant A Talwalkar
Journal:  J Clin Gastroenterol       Date:  2007 May-Jun       Impact factor: 3.062

Review 10.  On the TRAIL to therapeutic intervention in liver disease.

Authors:  Ingrid Herr; Peter Schemmer; Markus W Büchler
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

View more
  46 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

2.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2).

Authors:  Nathan W Werneburg; Steve F Bronk; Maria Eugenia Guicciardi; Laurel Thomas; Jimmy D Dikeakos; Gary Thomas; Gregory J Gores
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

3.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

Review 4.  Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines.

Authors:  Andrew M Miller; Norio Horiguchi; Won-Il Jeong; Svetlana Radaeva; Bin Gao
Journal:  Alcohol Clin Exp Res       Date:  2011-02-01       Impact factor: 3.455

5.  Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Fernando J Barreyro; Maria E Guicciardi; Yuko Akazawa; Karen Braley; Ruth W Craig; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

Review 6.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

Review 7.  Tissue-specific effector functions of innate lymphoid cells.

Authors:  Niklas K Björkström; Eliisa Kekäläinen; Jenny Mjösberg
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

8.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Authors:  Kazuyoshi Takeda; Yuko Kojima; Kenichi Ikejima; Kenichi Harada; Shunhei Yamashina; Kyoko Okumura; Tomonori Aoyama; Steffen Frese; Hiroko Ikeda; Nicole M Haynes; Erika Cretney; Hideo Yagita; Noriyoshi Sueyoshi; Nobuhiro Sato; Yasuni Nakanuma; Mark J Smyth; Ko Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

9.  CCR1 and CCR5 promote hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

10.  Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Steven F Bronk; Sophie Cazanave; Nathan W Werneburg; Justin L Mott; Patricia C Contreras; Gregory J Gores
Journal:  Hepatol Res       Date:  2009-07-13       Impact factor: 4.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.